HALO
Price
$54.00
Change
+$0.16 (+0.30%)
Updated
Jul 3 closing price
Capitalization
6.65B
38 days until earnings call
MDGL
Price
$298.87
Change
-$1.28 (-0.43%)
Updated
Jul 3 closing price
Capitalization
6.64B
32 days until earnings call
Interact to see
Advertisement

HALO vs MDGL

Header iconHALO vs MDGL Comparison
Open Charts HALO vs MDGLBanner chart's image
Halozyme Therapeutics
Price$54.00
Change+$0.16 (+0.30%)
Volume$868.07K
Capitalization6.65B
Madrigal Pharmaceuticals
Price$298.87
Change-$1.28 (-0.43%)
Volume$108.67K
Capitalization6.64B
HALO vs MDGL Comparison Chart in %
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. MDGL commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a StrongBuy and MDGL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (HALO: $54.00 vs. MDGL: $298.87)
Brand notoriety: HALO and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 29% vs. MDGL: 34%
Market capitalization -- HALO: $6.65B vs. MDGL: $6.64B
HALO [@Biotechnology] is valued at $6.65B. MDGL’s [@Biotechnology] market capitalization is $6.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 1 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 1 green, 4 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 3 TA indicator(s) are bullish while MDGL’s TA Score has 5 bullish TA indicator(s).

  • HALO’s TA Score: 3 bullish, 3 bearish.
  • MDGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than HALO.

Price Growth

HALO (@Biotechnology) experienced а +2.80% price change this week, while MDGL (@Biotechnology) price change was -0.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

HALO is expected to report earnings on Aug 12, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($6.65B) and MDGL($6.64B) have the same market capitalization . HALO YTD gains are higher at: 12.947 vs. MDGL (-3.144). HALO has higher annual earnings (EBITDA): 705M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. HALO (748M). MDGL has less debt than HALO: MDGL (120M) vs HALO (1.51B). HALO has higher revenues than MDGL: HALO (1.08B) vs MDGL (317M).
HALOMDGLHALO / MDGL
Capitalization6.65B6.64B100%
EBITDA705M-376.15M-187%
Gain YTD12.947-3.144-412%
P/E Ratio14.36N/A-
Revenue1.08B317M342%
Total Cash748M843M89%
Total Debt1.51B120M1,256%
FUNDAMENTALS RATINGS
HALO vs MDGL: Fundamental Ratings
HALO
MDGL
OUTLOOK RATING
1..100
5214
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
4042
SMR RATING
1..100
1297
PRICE GROWTH RATING
1..100
5857
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (64) in the Pharmaceuticals Other industry is in the same range as HALO (75) in the Biotechnology industry. This means that MDGL’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (40) in the Biotechnology industry is in the same range as MDGL (42) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to MDGL’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for MDGL (97) in the Pharmaceuticals Other industry. This means that HALO’s stock grew significantly faster than MDGL’s over the last 12 months.

MDGL's Price Growth Rating (57) in the Pharmaceuticals Other industry is in the same range as HALO (58) in the Biotechnology industry. This means that MDGL’s stock grew similarly to HALO’s over the last 12 months.

HALO's P/E Growth Rating (90) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that HALO’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOMDGL
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
72%
MACD
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
68%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
63%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RAFFX46.000.48
+1.05%
American Funds AMCAP R5
BNSCX16.630.13
+0.79%
UBS US Small Cap Growth A
GSMSX36.050.21
+0.59%
Goldman Sachs Mid Cap Value Svc
LRSRX13.550.08
+0.59%
Lord Abbett Small Cap Value R3
INSLX43.41-0.10
-0.23%
Invesco International Small-Mid Com R5